These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15603511)

  • 21. Wild-type p53 in cancer cells: when a guardian turns into a blackguard.
    Kim E; Giese A; Deppert W
    Biochem Pharmacol; 2009 Jan; 77(1):11-20. PubMed ID: 18812169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.
    Chira S; Gulei D; Hajitou A; Berindan-Neagoe I
    Trends Biotechnol; 2018 Jul; 36(7):653-660. PubMed ID: 29478674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting p53 in cancer.
    Chène P
    Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):151-61. PubMed ID: 12678764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
    Menendez JA; Lupu R
    Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA.
    Shin KS; Sullenger BA; Lee SW
    Mol Ther; 2004 Aug; 10(2):365-72. PubMed ID: 15294183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel cancer therapy by reactivation of the p53 apoptosis pathway.
    Bykov VJ; Wiman KG
    Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methods for screening tumors for p53 status and therapeutic exploitation.
    Tullo A; D'Erchia AM; Sbisà E
    Expert Rev Mol Diagn; 2003 May; 3(3):289-301. PubMed ID: 12779005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.
    Harris CC
    J Natl Cancer Inst; 1996 Oct; 88(20):1442-55. PubMed ID: 8841019
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy.
    Bossi G; Sacchi A
    Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-transfer of human wild-type p53 and granulocyte-macrophage colony-stimulating factor genes via recombinant adenovirus induces apoptosis and enhances immunogenicity in laryngeal cancer cells.
    Qiu Z; Lao M; Wu C
    Cancer Lett; 2001 Jun; 167(1):25-32. PubMed ID: 11323095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms.
    Bug M; Dobbelstein M
    Oncogene; 2011 Aug; 30(33):3612-24. PubMed ID: 21441950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Damage-inducible intragenic demethylation of the human TP53 tumor suppressor gene is associated with transcription from an alternative intronic promoter.
    Blackburn J; Roden DL; Ng R; Wu J; Bosman A; Epstein RJ
    Mol Carcinog; 2016 Dec; 55(12):1940-1951. PubMed ID: 26676339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
    Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
    Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting p53 as a promising therapeutic option for cancer by re-activating the wt or mutant p53's tumor suppression.
    Węsierska-Gądek J
    Future Med Chem; 2018 Apr; 10(7):755-777. PubMed ID: 29569948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.